384 related articles for article (PubMed ID: 33533091)
1. Experience with oral tofacitinib in severe alopecia areata with different clinical responses.
Dincer Rota D; Emeksiz MAC; Erdogan FG; Yildirim D
J Cosmet Dermatol; 2021 Sep; 20(9):3026-3033. PubMed ID: 33533091
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
5. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata.
Akdogan N; Ersoy-Evans S; Doğan S; Atakan N
Dermatol Ther; 2019 Nov; 32(6):e13118. PubMed ID: 31621150
[TBL] [Abstract][Full Text] [Related]
6. A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis.
Sharath S; Sardana K; Khurana A
Indian Dermatol Online J; 2024; 15(1):49-54. PubMed ID: 38282998
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
10. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
Kibbie J; Kines K; Norris D; Dunnick CA
Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
[TBL] [Abstract][Full Text] [Related]
11. Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy.
Oba MC; Askin O; Balci Ekmekci O; Serdaroglu S
J Cosmet Dermatol; 2021 Mar; 20(3):971-975. PubMed ID: 32808476
[TBL] [Abstract][Full Text] [Related]
12. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study.
Jerjen R; Meah N; Trindade de Carvalho L; Wall D; Eisman S; Sinclair R
Pediatr Dermatol; 2021 Jan; 38(1):103-108. PubMed ID: 33099833
[TBL] [Abstract][Full Text] [Related]
13. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
Erduran F; Adışen E; Aksakal AB
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Yu L; Yu H; Zhang S; Hao Y; Zhang S
Front Immunol; 2022; 13():904156. PubMed ID: 35795663
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Dincer D; Tanacan E; Kose Ozkan C
J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
Shivanna CB; Shenoy C; Priya RA
Int J Trichology; 2018; 10(3):103-107. PubMed ID: 30034188
[TBL] [Abstract][Full Text] [Related]
18. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population.
AlMarzoug A; AlOrainy M; AlTawil L; AlHayaza G; AlAnazi R; AlIssa A; AlSheikh A; AlKhalifah A; AlHarithy R
Int J Dermatol; 2022 Jul; 61(7):886-894. PubMed ID: 34716573
[TBL] [Abstract][Full Text] [Related]
19. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
